MP
KALV

Mangrove Partners’s KalVista Pharmaceuticals KALV Stock Holding History

Mangrove Partners’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-92,000
Closed -$1.22M – 469
2021
Q4 		$1.22M Buy
+92,000
New +$1.46M 0.07% 412

Other funds holding KALV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Mangrove Partners's KALV Position: Q1 2022 in Review

Mangrove Partners sold out of KalVista Pharmaceuticals (KALV) in Q1 2022, closing a stake of 92,000 shares — an estimated $1.22M sold.

Mangrove Partners first reported a position in KALV in Q4 2021 and held it in 1 quarter. The position peaked at $1.22M in Q4 2021. 89 funds tracked by Wall St. Rank hold KALV as of Q1 2022.

  • Mangrove Partners reported no remaining KalVista Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Mangrove Partners sold 92,000 KalVista Pharmaceuticals shares in Q1 2022, an estimated $1.22M.
  • Mangrove Partners first reported a position in KalVista Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Mangrove Partners's KalVista Pharmaceuticals position peaked at $1.22M in Q4 2021.
  • 89 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2022.

Based on Mangrove Partners's 13F filing for Q1 2022, filed 16 May 2022.